Saga Diagnostics
Saga Diagnostics specializes in ultrasensitive cancer diagnostics and monitoring using a simple blood test. Their technology, SAGAsafe®, detects and quantifies mutations with unparalleled sensitivity, revolutionizing the field of oncology. With over 250 validated assays, Saga Diagnostics offers insights to expedite new drug approvals and enhance patient care. They also offer SAGAsign®, a unique hybrid method for monitoring response to therapy and detecting minimal residual disease and recurrences. In addition, Saga Diagnostics is developing SAGAseq®, a platform that combines enhanced sequencing library preparation with AI/machine learning bioinformatics to improve accuracy. Their services have been validated in clinical studies, demonstrating the predictive power of their technologies. Based in Lund, Sweden, Saga Diagnostics is a gamechanger for the biopharmaceutical industry.